Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 4

APPLIED GENETIC TECHNOLOGI Form 4	ES CORP			
August 18, 2016 FORM 4 UNITED STATE	S SECURITIES AND EXCHANGE	COMMISSION		PPROVAL
Check this box	Washington, D.C. 20549	COMMINISSION	OMB Number:	3235-0287 January 31
if no longer subject to Section 16.STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESForm 4 or Form 5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,			Expires: Estimated a burden hou response	2005 average rs per
obligations may continue Section 17(a) of the	Public Utility Holding Company Act of 19	of 1935 or Section	L	
(Print or Type Responses)				
1. Name and Address of Reporting Person <u>*</u> VANLENT ANNE	2. Issuer Name and Ticker or Trading Symbol APPLIED GENETIC TECHNOLOGIES CORP [AGTC]	5. Relationship of I Issuer (Check	Reporting Pers	
(Last) (First) (Middle) C/O APPLIED GENETIC TECHNOLOGIES CORP., 14193 NW 119TH TERRACE, SUITE #10	3. Date of Earliest Transaction (Month/Day/Year) 08/17/2016	X Director Officer (give to below)		o Owner er (specify
(Street) ALACHUA, FL 32615	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)	Table I - Non-Derivative Securities Ac		or Beneficial	ly Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deen Execution any (Month/E	n Date, if TransactionAcquired (A) or Code Disposed of (D) Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A) or	Beneficially (D Owned (I)	orm: Direct)) or Indirect	Indirect
Reminder: Report on a separate line for each of	Code V Amount (D) Price			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 2 4. 8 Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date** Underlying Securities Ľ (Instr. 3 and 4) Security or Exercise any Code Securities (Month/Day/Year) S Price of (Month/Day/Year) (Instr. 8) (Instr. 3) Acquired (A) (Derivative or Disposed of Security (D) (Instr. 3, 4, and 5) Code V (A) (D) Date Expiration Title Amount Exercisable Date or Number of Shares Stock Option Common \$15.13 08/17/2016 16,000 (1) 08/17/2026 16,000 Α Stock (right to buy) **Reporting Owners** Relationships **Reporting Owner Name / Address** Director 10% Owner Officer Other VANLENT ANNE C/O APPLIED GENETIC TECHNOLOGIES CORP. X 14193 NW 119TH TERRACE, SUITE #10 ALACHUA, FL 32615 **Signatures** /s/Hemmie Chang, attorney-in-fact for Anne M. 08/18/2016 VanLent **Signature of Reporting Person Date **Explanation of Responses:** If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 4

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Option becomes exercisable in equal yearly installments over three years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.